FDA, Peter Marks
Digest more
Top News
Impacts
Robert F. Kennedy Jr. forcing Peter Marks out of the Food and Drug Administration has blown a hole in the agency’s leadership ranks and threatens to unmoor the oversight of drugs and vaccines from bed...
From STAT
Biotech investors are reeling after the sudden departure of Dr. Peter Marks, a pivotal figure in the U.S. Food and Drug Administration.
From Wall Street Journal
Read more on News Digest
As the FDA wavers from cuts, changes and departures under the second Trump administration, another vital figure of the agency is heading for the exit. | In resigning as director of the FDA’s Center for Biologics Evaluation and Research,
Top FDA official Peter Marks was forced to resign as the director of the Center for Biologics Evaluation and Research.
Marks offered his resignation while citing Kennedy’s “misinformation and lies” and an “unprecedented assault on scientific truth” impacting public health.
In his resignation letter, Marks cited disagreement with HHS Secretary Robert F. Kennedy Jr., who he said pushed “misinformation and lies.”
The sudden departure of Peter Marks, MD, from the FDA has prompted a chorus of criticism and despair from industry leaders and trade organizations.
Explore more
Biotech stocks plunge after Dr. Peter Marks resigns from FDA, citing disputes with RFK Jr. over vaccines and drug approvals. Investors fear regulatory uncertainty.
Dr. Peter Marks, the Food and Drug Administration’s top vaccine regulator, has resigned, an official at the Department of Health and Human Services said Friday.
BMO Capital analysts view the departure of Dr. Peter Marks from the FDA as a “significant negative” for the biopharma and biotech sectors. The